home / stock / grts / grts quote
Last: | $0.8134 |
---|---|
Change Percent: | 0.81% |
Open: | $0.7583 |
Close: | $0.8134 |
High: | $0.8356 |
Low: | $0.7583 |
Volume: | 1,106,265 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.8134 | $0.7583 | $0.8134 | $0.8356 | $0.7583 | 1,106,265 | 04-26-2024 |
$0.7645 | $0.81 | $0.7645 | $0.81 | $0.753 | 1,068,630 | 04-25-2024 |
$0.8129 | $0.7362 | $0.8129 | $0.82 | $0.7257 | 1,870,771 | 04-24-2024 |
$0.7386 | $0.73 | $0.7386 | $0.784 | $0.72065 | 2,406,490 | 04-23-2024 |
$0.7455 | $0.727 | $0.7455 | $0.76 | $0.685 | 3,390,234 | 04-22-2024 |
$0.7366 | $0.746 | $0.7366 | $0.7777 | $0.7088 | 1,532,645 | 04-19-2024 |
$0.7437 | $0.7417 | $0.7437 | $0.774 | $0.724 | 2,106,150 | 04-18-2024 |
$0.7452 | $0.79 | $0.7452 | $0.7949 | $0.7362 | 3,114,399 | 04-17-2024 |
$0.7719 | $0.7262 | $0.7719 | $0.8435 | $0.6716 | 4,527,793 | 04-16-2024 |
$0.7389 | $0.8575 | $0.7389 | $0.868199 | $0.72 | 5,732,317 | 04-15-2024 |
$0.8411 | $0.93 | $0.8411 | $0.93 | $0.828 | 4,337,637 | 04-12-2024 |
$0.9221 | $0.9622 | $0.9221 | $0.9622 | $0.9151 | 2,401,180 | 04-11-2024 |
$0.9463 | $0.97 | $0.9463 | $0.9835 | $0.93 | 6,733,463 | 04-10-2024 |
$0.9787 | $1.03 | $0.9787 | $1.045 | $0.9604 | 2,511,898 | 04-09-2024 |
$1.01 | $1 | $1.01 | $1.05 | $0.99 | 3,864,614 | 04-08-2024 |
$0.9702 | $1.02 | $0.9702 | $1.06 | $0.9458 | 7,300,419 | 04-05-2024 |
$1.035 | $1.18 | $1.035 | $1.18 | $0.99995 | 9,628,573 | 04-04-2024 |
$1.19 | $1.22 | $1.19 | $1.23 | $1.17 | 4,852,620 | 04-03-2024 |
$1.2 | $1.3 | $1.2 | $1.37 | $1.16 | 25,473,238 | 04-02-2024 |
$2.35 | $2.67 | $2.35 | $2.67 | $2.28 | 7,900,749 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS...
-- State-of-the-art neoantigen prediction platform (EDGE ™ ) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly...
NEW YORK, NY / ACCESSWIRE / April 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ:GRTS). Investors who purchased Gritstone securities are encouraged to obtain additional infor...